Stocklytics Platform
Asset logo for symbol ARWR
Arrowhead Pharmaceuticals
ARWR57
$19.95arrow_drop_up4.39%$0.83
Asset logo for symbol ARWR
ARWR57

$19.95

arrow_drop_up4.39%
Key Stats
Open$19.27
Prev. Close$19.11
EPS-5.38
DividendNon-Dividend
Next Earnings Date-
Dividend Yield %-
PE Ratio-
LOWHIGH
Day Range18.81
20.18
52 Week Range17.57
39.83
Ratios
EPS-5.38
Fundamentals
Payout Ratio-
Industry average yield2.99%
Last Dividend pay date-
Dividend per share-
Dividend yield forecast-

Stock Analysis

Technicals

Summarizing what the indicators are suggesting.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Analyst rating

An aggregate view of professional's ratings.

Strong Buy
Buy
Neutral
Sell
Strong Sell

Stock Performance

ARWR-
US Healthcare Sector-
US Market-
check_circle

ARWR / Market

ARWR exceeded the US Market which returned -0.15% over the last twenty four hours.
check_circle

ARWR / Healthcare Sector

ARWR exceeded the US Healthcare sector which returned 1.08% over the last twenty four hours.

Arrowhead Pharmaceuticals (ARWR) Statistics

Arrowhead Pharmaceuticals Inc. (ARWR) is a biopharmaceutical company engaged in the development of RNA interference (RNAi) therapies for intractable diseases. The company utilizes its proprietary Targeted RNAi Molecule (TRiM™) platform to design and develop RNAi drugs that can selectively silence disease-causing genes. With a focus on liver-targeted therapies, Arrowhead has made significant advancements in the treatment of rare genetic disorders, as well as chronic hepatitis B and alpha-1 antitrypsin deficiency. The company's innovative approach has garnered recognition and partnerships with leading pharmaceutical companies.
When it comes to valuation metrics, Arrowhead Pharmaceuticals Inc.'s stock (ARWR) appears to be significantly undervalued. With a price-to-sales ratio of 38.80, the company's stock trades at a substantial discount compared to its industry peers. This suggests that investors have yet to fully recognize the company's growth potential and the value of its RNAi drug pipeline. Furthermore, Arrowhead's enterprise value-to-EBITDA ratio of 14.32 indicates that the company is generating strong operating profits relative to its debt obligations.
add Arrowhead Pharmaceuticals  to watchlist

Keep an eye on Arrowhead Pharmaceuticals

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

search
help

How much debt does Arrowhead Pharmaceuticals (ARWR) have?

Arrowhead Pharmaceuticals (ARWR) has a total debt of $872.05M. The net debt, which accounts for cash and cash equivalents against the total debt, is $61.97M.
help

How has Arrowhead Pharmaceuticals (ARWR) stock's performance compared to its sector and the market over the past year?

Over the past year, Arrowhead Pharmaceuticals (ARWR) has experienced a price change of . Compared to the Healthcare sector, which saw a change of 18.23%, Arrowhead Pharmaceuticals has underperformed compared to its sector, indicating its relative standing within the Healthcare sector. Against the broader market's change of 39.33%, it has fallen short of the market average. This comparison highlights Arrowhead Pharmaceuticals 's performance relative to both its sector and the overall market over the last year.
help

What is the PE ratio of Arrowhead Pharmaceuticals (ARWR) stock?

The PE ratio for Arrowhead Pharmaceuticals (ARWR) is currently not available. This could be due to a variety of factors such as the company not having positive earnings at the moment or recent updates not being reflected.
help

What is the EPS of Arrowhead Pharmaceuticals (ARWR) stock?

The Earnings Per Share (EPS) for Arrowhead Pharmaceuticals (ARWR), calculated on a diluted basis, is -$5.38. EPS is a key indicator of a company's profitability, showing the portion of a company's profit allocated to each outstanding share of common stock.
help

What is the operating margin of Arrowhead Pharmaceuticals (ARWR) stock?

The operating margin for Arrowhead Pharmaceuticals (ARWR) is -6.46K%. This metric represents the percentage of revenue that remains after paying for variable production costs, indicating the efficiency and profitability of the company's core business operations.
help

What is the EBITDA of Arrowhead Pharmaceuticals (ARWR) stock?

The EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) of Arrowhead Pharmaceuticals (ARWR) is -$606.38M. EBITDA is a widely used earnings metric to assess a company's operational efficiency and profitability before the impact of non-operating decisions such as financing, accounting, and tax environments.

Take Your Investments to a Whole New Level